HCP
FOLD

Hexagon Capital Partners’s Amicus Therapeutics FOLD Stock Holding History

Hexagon Capital Partners’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-640
Closed -$5.22K – 662
2025
Q1 		$5.22K Buy
640
+56
+10% +$518 ﹤0.01% 1157
2024
Q4 		$5.5K Buy
584
+277
+90% +$2.88K ﹤0.01% 1183
2024
Q3 		$3.28K Hold
307
– – ﹤0.01% 1135
2024
Q2 		$3.05K Buy
+307
New +$3.15K ﹤0.01% 1092

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Hexagon Capital Partners's FOLD Position: Q2 2025 in Review

Hexagon Capital Partners sold out of Amicus Therapeutics (FOLD) in Q2 2025, closing a stake of 640 shares — an estimated $5.22K sold.

Hexagon Capital Partners first reported a position in FOLD in Q2 2024 and held it in 4 quarters. The position peaked at $5.5K in Q4 2024. 272 funds tracked by Wall St. Rank hold FOLD as of Q2 2025.

  • Hexagon Capital Partners reported no remaining Amicus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 640 Amicus Therapeutics shares in Q2 2025, an estimated $5.22K.
  • Hexagon Capital Partners first reported a position in Amicus Therapeutics in Q2 2024 and held it in 4 quarters.
  • Hexagon Capital Partners's Amicus Therapeutics position peaked at $5.5K in Q4 2024.
  • 272 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2025.

Based on Hexagon Capital Partners's 13F filing for Q2 2025, filed 11 Aug 2025.